Tessoulin, B., Thomare, P., Delande, E., Moynard, J., Gastinne, T., Moreau, A., Bossard, C., Mahé, B., Blin, N., Dubruille, V., Touzeau, C., Boudreault, J.S., Perrin, F., Lok, A., Guillaume, T., Garnier, A., Peterlin, P., Gallas, P., Chevallier, P. and Moreau, P. (2017) Carboplatin Instead of Cisplatin in Combination with Dexamethasone, High-Dose Cytarabine with or without Rituximab (DHAC+/-R) Is An Effective Treatment with Low Toxicity in Hodgkin’s and Non-Hodgkin’s Lymphoma. Annals of Hematology, 96, 943-950.
https://doi.org/10.1007/s00277-017-2981-2

has been cited by the following article:

• TITLE: The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion

  AUTHORS: Arthur J. Weiss, Irwin L. Stoloff, Antonio C. Simoes

  KEYWORDS: Doxorubicin Infusion Dendritic, Killer Cells

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.7, July 18, 2017

  ABSTRACT: It has been demonstrated that it is safe to give Gm-Csf, together with Doxorubicin, by continuous intravenous infusion, thereby substantially increasing the amount of Doxorubicin administered to the average patient, and assuring that each patient receives an individually-determined safe and maximal amount of drug. It is known that Gm-Csf is a potent inducer of components that are major factors in an immunologic attack upon neoplasms. For that reason, we thought it would be worth evaluating in 4 patients’ surface markers of dendritic precursor cells, dendritic cells [DC], and natural killer [NK] cells during the infusion. While there was substantial variation in individual responses, all 4 patients receiving Gm-Csf developed persistent marked increases in cells with each of these markers. The significance of these findings will be discussed.